Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles A Mebus

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Rheumatology (Oxford, England)|May 2, 2017
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trialsRegina Rendas-Baum, Mark Kosinski, Amitabh Singh, et al.
Clinical and Experimental Rheumatology|November 18, 2015
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and IIIStanley B Cohen, Andrew Koenig, Lisy Wang, et al.
Clinical and Experimental Rheumatology|January 13, 2017
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritisJeffrey R Curtis, Hendrik Schulze-Koops, Liza Takiya, et al.
The Journal of Rheumatology|March 3, 2012
Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexateThomas C Stock, Bradley J Bloom, Nathan Wei, et al.
Arthritis Care & Research|September 5, 2014
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trialVibeke Strand, Gerd R Burmester, Cristiano A F Zerbini, et al.
Science (New York, N.Y.)|September 18, 2012
Rinderpest eradication: appropriate technology and social innovationsJeffrey C Mariner, James A House, Charles A Mebus, et al.
Arthritis Research & Therapy|January 19, 2012
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trialDona L Fleishaker, Juan A Garcia Meijide, Andriy Petrov, et al.
Pediatric Rheumatology Online Journal|December 29, 2017
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter studyNicolino Ruperto, Hermine I Brunner, Zbigniew Zuber, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Rheumatology (Oxford, England)|May 2, 2017
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trialsRegina Rendas-Baum, Mark Kosinski, Amitabh Singh, et al.
Clinical and Experimental Rheumatology|November 18, 2015
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and IIIStanley B Cohen, Andrew Koenig, Lisy Wang, et al.
Clinical and Experimental Rheumatology|January 13, 2017
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritisJeffrey R Curtis, Hendrik Schulze-Koops, Liza Takiya, et al.
The Journal of Rheumatology|March 3, 2012
Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexateThomas C Stock, Bradley J Bloom, Nathan Wei, et al.
Arthritis Care & Research|September 5, 2014
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trialVibeke Strand, Gerd R Burmester, Cristiano A F Zerbini, et al.
Science (New York, N.Y.)|September 18, 2012
Rinderpest eradication: appropriate technology and social innovationsJeffrey C Mariner, James A House, Charles A Mebus, et al.
Arthritis Research & Therapy|January 19, 2012
Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trialDona L Fleishaker, Juan A Garcia Meijide, Andriy Petrov, et al.
Pediatric Rheumatology Online Journal|December 29, 2017
Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter studyNicolino Ruperto, Hermine I Brunner, Zbigniew Zuber, et al.
Pageof 1